Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Developing a novel allogeneic chimeric antigen receptor-modified double-negative T cell (CAR-DNT) therapy for the treatment of chemotherapy-resistant CD4+ T-cell acute lymphoblastic leukemia (T-ALL)

EF 2018-19

Résumé
Lasting remissions from induction chemotherapy for T-cell acute lymphoblastic leukemia (T-ALL) are rare and long-term survival for relapsed patients is below 7%. There is an unmet need for a safer and more effective treatment for chemotherapy-resistant T-ALL. Chimeric antigen receptor-modified T cell (CAR-T) therapies are effective but current CAR-carrier cells still face issues with fratricide, graft-versus-host disease (GvHD), in vivo tumorigenesis and short persistence. Our group initially characterized double negative T cells (DNTs), a subset of mature CD3+CD4-CD8- T cells, and developed a protocol to expand them ex vivo from the peripheral blood of healthy donors. We have extensively characterized the safety and efficacy of allogeneic DNTs as an adoptive cellular therapy (ACT) for leukemia. Also, DNTs fulfill the requirements of an off-the-shelf (OtS) ACT including donor-independent function, no GvHD, cryo-preservability, resistance to host-versus-graft (HvG) rejection and no observed off-tumor toxicity. The objective of this project is to develop a safer and more effective ACT against T-ALL by combining the potency of CAR technology with the OtS properties of DNTs. In particular, we aim to take advantage of using DNTs as a cell vehicle by targeting the CD4 T-lineage molecule found on T-ALL. In addition to fratricide-free manufacturing of CAR4-DNTs, we hypothesize they will not cause GvHD and will have a tolerable degree of on-target, off-tumor toxicity. This project will determine the safety and efficacy of CAR4-DNTs against CD4+ T-ALL, a potential novel therapeutic option for chemotherapy-resistant T-ALL. Also, these studies will provide insight into the generalized application of DNTs as an OtS CAR-vehicle beyond ALL.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
411303
Name
Vasic Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a novel allogeneic chimeric antigen receptor-modified double-negative T cell (CAR-DNT) therapy for the treatment of chemotherapy-resistant CD4+ T-cell acute lymphoblastic leukemia (T-ALL)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Healthy-Donor Derived Immunotherapy; Adoptive Cellular Therapy; Allogeneic; Cancer Immunotherapy; Chimeric Antigen Receptor-Modified T Cells; Double-Negative T Cells; Leukemias; Novel Immunotherapy; Off-The-Shelf Immunotherapy; T-Cell Acute Lymphoblastic Leukemia
Abstract
Lasting remissions from induction chemotherapy for T-cell acute lymphoblastic leukemia (T-ALL) are rare and long-term survival for relapsed patients is below 7%. There is an unmet need for a safer and more effective treatment for chemotherapy-resistant T-ALL. Chimeric antigen receptor-modified T cell (CAR-T) therapies are effective but current CAR-carrier cells still face issues with fratricide, graft-versus-host disease (GvHD), in vivo tumorigenesis and short persistence. Our group initially characterized double negative T cells (DNTs), a subset of mature CD3+CD4-CD8- T cells, and developed a protocol to expand them ex vivo from the peripheral blood of healthy donors. We have extensively characterized the safety and efficacy of allogeneic DNTs as an adoptive cellular therapy (ACT) for leukemia. Also, DNTs fulfill the requirements of an off-the-shelf (OtS) ACT including donor-independent function, no GvHD, cryo-preservability, resistance to host-versus-graft (HvG) rejection and no observed off-tumor toxicity. The objective of this project is to develop a safer and more effective ACT against T-ALL by combining the potency of CAR technology with the OtS properties of DNTs. In particular, we aim to take advantage of using DNTs as a cell vehicle by targeting the CD4 T-lineage molecule found on T-ALL. In addition to fratricide-free manufacturing of CAR4-DNTs, we hypothesize they will not cause GvHD and will have a tolerable degree of on-target, off-tumor toxicity. This project will determine the safety and efficacy of CAR4-DNTs against CD4+ T-ALL, a potential novel therapeutic option for chemotherapy-resistant T-ALL. Also, these studies will provide insight into the generalized application of DNTs as an OtS CAR-vehicle beyond ALL.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vasic, Daniel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~